Table 1 Patient characteristics
Characteristic | N =120 (%) |
|---|---|
Median follow-up | 49.9 months |
(range) | (3.3–97.6) |
Median age | 57 years |
(range) | (33–80) |
Sex | |
Female | 29 (24) |
Male | 91 (76) |
Performance status | |
0 | 2 (2) |
1 | 118 (98) |
HPV status | |
Positive | 74 (62) |
Negative | 26 (22) |
Unknown | 20 (16) |
Tumour site | |
Oropharynx | 110 (92) |
Hypopharynx | 10 (8) |
T stage | |
T1 | 25 |
T2 | 51 |
T3 | 23 |
T4 | 21 |
N stage | |
N0 | 23 |
N1 | 17 |
N2a | 10 |
N2b | 46 |
N2c | 22 |
N3 | 2 |
AJCC stage | |
I | 1 (1) |
II | 10 (8) |
III | 19 (16) |
IVa | 88 (73) |
IVb | 2 (2) |
Induction chemotherapy | |
Cisplatin+5-Flurouracil (PF) | 69 (58) |
Carboplatin+5-Flurouracil (Carbo-F) | 7 (6) |
1PF+1 Carbo-F | 5 (4) |
1PF or 1 Carbo-F | 2 (2) |
Docetaxel+Cisplatin+5-Flurouracil | 3 (3) |
Concomitant chemotherapy | |
Cisplatin (P) | 65 (54) |
Carboplatin (carbo) | 20 (17) |
1 P +1 Carbo | 14 (12) |
Cetuximab | 2 (2) |
Radiotherapy | |
Primary | 103 (87) |
Postoperative | 17 (13) |
